{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:16:03Z","timestamp":1783163763934,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["RWIA-21-123-01-RWIA"],"award-info":[{"award-number":["RWIA-21-123-01-RWIA"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:08:38Z","timestamp":1778760518000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-9624","authenticated-orcid":false,"given":"Gretchen","family":"Kimmick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asal","family":"Pilehvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloribel","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger T","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2026.04.012_bib0001","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12885-022-10098-1","article-title":"Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden","volume":"22","author":"Lindman","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0002","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41416-022-01845-z","article-title":"Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study","volume":"127","author":"Valachis","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.012_bib0003","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000519729","article-title":"Objective response to first-line treatment as a predictor of overall survival in metastatic breast cancer: a retrospective analysis from two centers over a 25-year period","volume":"17","author":"Matikas","year":"2022","journal-title":"Breast Care (Basel)"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.012_bib0004","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.012_bib0005","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.04.012_bib0006","article-title":"The effect of Abemaciclib Plus Fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","author":"Sledge","year":"2019","journal-title":"JAMA oncology"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20312","article-title":"Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.012_bib0008","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, Human epidermal growth factor receptor 2-negative metastatic breast cancer-Capivasertib-Fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.012_bib0009","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.21037\/atm-21-5110","article-title":"Pharmacoeconomic evaluations of CDK4\/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review","volume":"10","author":"Zhu","year":"2022","journal-title":"Annals of translational medicine"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40261-024-01416-5","article-title":"The cost-effectiveness of CDK4\/6 inhibitors in treating HR+\/HER2- metastatic breast cancer patients in the USA: when non-medication expenses are considered","volume":"45","author":"Pilehvari","year":"2025","journal-title":"Clinical drug investigation"},{"issue":"8042","key":"10.1016\/j.clbc.2026.04.012_bib0012","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-024-07415-6","article-title":"First- vs second-line CDK 4\/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting","volume":"208","author":"Kimmick","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.012_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13058-025-02095-6","article-title":"Comparative efficacy of first- versus second-line CDK4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"27","author":"Ravani","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104125","article-title":"Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world","volume":"10","author":"Blondeaux","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.clbc.2026.04.012_bib0016","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.012_bib0017","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.clbc.2026.04.012_bib0018","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10063","key":"10.1016\/j.clbc.2026.04.012_bib0019","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.012_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"32","key":"10.1016\/j.clbc.2026.04.012_bib0021","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib As initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clbc.2026.04.012_bib0022","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.012_bib0023","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.012_bib0024","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.012_bib0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-024-01902-w","article-title":"Disparities in receipt of 1-(st) line CDK4\/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting","volume":"26","author":"Pilehvari","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0027","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study","volume":"136","author":"Robertson","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.04.012_bib0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.012_bib0029","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nature reviews. Cancer"},{"key":"10.1016\/j.clbc.2026.04.012_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115113","article-title":"The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study","volume":"213","author":"Molinelli","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0031","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer cell"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.012_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038798","article-title":"Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital","volume":"10","author":"Karihtala","year":"2020","journal-title":"BMJ open"},{"key":"10.1016\/j.clbc.2026.04.012_bib0033","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/1097-0142(19910815)68:4<867::AID-CNCR2820680432>3.0.CO;2-H","article-title":"The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen","volume":"68","author":"Bezwoda","year":"1991","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","article-title":"Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study","volume":"89","author":"Elledge","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2026.04.012_bib0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.1992.10.8.1284","article-title":"Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study","volume":"10","author":"Ravdin","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0036","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.012_bib0037","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","article-title":"Correlations between estrogen-receptor, progesterone-receptor, and patient characteristics in Human-breast cancer","volume":"2","author":"Clark","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.012_bib0038","first-page":"505","article-title":"Oestrogen and progesterone receptor determinations in breast cancer: technology and biology","volume":"5","author":"Thorpe","year":"1986","journal-title":"Cancer Surv"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.012_bib0039","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0959-8049(94)00496-R","article-title":"Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group","volume":"31A","author":"Romain","year":"1995","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.012_bib0040","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2009.25.9796","article-title":"Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival","volume":"28","author":"Schonberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.012_bib0041","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jama.2012.84","article-title":"Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer","volume":"307","author":"van de Water","year":"2012","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.012_bib0042","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1,038 women with metastatic breast cancer","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.04.012_bib0043","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1200\/JCO.1987.5.1.55","article-title":"Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients","volume":"5","author":"Clark","year":"1987","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.012_bib0044","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2015.127","article-title":"Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?","volume":"112","author":"Lobbezoo","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2026.04.012_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.humpath.2017.10.002","article-title":"Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important","volume":"70","author":"Shen","year":"2017","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.012_bib0046","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.breast.2009.09.002","article-title":"The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors","volume":"18","author":"Stuart-Harris","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.04.012_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104412","article-title":"Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer","volume":"80","author":"Walter","year":"2025","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0048","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"Sorensen","year":"1993","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0049","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2012.01.004","article-title":"Adjuvant radiation and outcomes after breast conserving surgery in publicly insured patients","volume":"3","author":"Kimmick","year":"2012","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.012_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227256","article-title":"Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer","volume":"15","author":"Huang Bartlett","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.012_bib0051","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.012_bib0052","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10549-013-2477-2","article-title":"Social networks, social support mechanisms, and quality of life after breast cancer diagnosis","volume":"139","author":"Kroenke","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"6797","key":"10.1016\/j.clbc.2026.04.012_bib0053","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.clbc.2026.04.012_bib0054","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.012_bib0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/his.14794","article-title":"Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction","volume":"82","author":"Nourieh","year":"2023","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.clbc.2026.04.012_bib0056","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:22:36Z","timestamp":1783160556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000649"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}